BIO's Testimony in Opposition to Maryland's House Bill 666

Patrick Plues, BIO’s Vice President, State Government Affairs, testified before the Maryland House in opposition to House Bill 666, which would require biopharmaceutical manufacturers to disclose specific information on cost inputs for specific drugs and to provide 60-day prior notice of any anticipated price increase for products priced over a certain threshold.